Narrative · → persistent Deployment is faster than evidence All narratives · 17 supporting stories · 0 from Hungary
„The number of FDA-approved AI tools is growing rapidly, and hospitals use them widely. Meanwhile, clinical benefits have been studied in less than 1% of tools, while hospital testing and oversight often lag behind.”
Counter-narrative According to the innovation leader at MD Anderson, hospitals are not falling behind. The counter-argument is that the pace of implementation does not mean loss of control.
Carriers PLOS Digital Health and JMIR analyses, CHAI, AMA, KLAS/UPMC CCM, ASCO, Nature Medicine, Imprivata, trade press
Analysis A recurring critical framing repeated across many sources. The numbers recur, and more and more actors cite them. It is fed by the growing number of authorizations: 1,357 or 1,430 devices as of 2025, more than 1,500 by mid-August, and more than 1,600 by October. Meanwhile, the evidence base is visibly lagging. One report, however, gives only figures above 1,000 and 1,200 respectively, which shows that the numbers differ by source. The framing serves the interests of the research and oversight community, as well as organizations urging responsible use (AMA, CHAI). Its weak point is that missing evidence is not the same as harm. For low-risk administrative tools, a demand for randomized trials may be disproportionate.
Evidence: moderate — The approval side is supported by registry analyses. PLOS Digital Health examined 1357 devices, of which 3 were tested on patients and 34 were registered for a prospective study. JMIR analysed 1430 devices, and according to reports clinical benefit was studied for fewer than 1% of the devices. The hospital side, by contrast, rests on surveys and vendor data: the 93/44% comes from an unnamed report, the deployment without approval from Imprivata, and the overall picture from press summaries. Device counts are not consistent across sources.
What's at stake: Whether the foundation of hospital AI trust will be measured outcomes or just a procurement list.
Narrative sub-threads The narrative splits into 4 branches; a story may belong to several branches, and some may not appear in the main narrative's list.
→ lasting · evidence: strong Number of approvals versus clinical evidence The number of FDA-approved AI devices was around 1,500 by mid-August and exceeded 1,600 in October according to compilations. Clinical evidence is far narrower: reports indicate clinical benefit was studied for less than 1% of devices. A PLOS Digital Health analysis found that of the 1,357 devices approved by December 5, 2025, only 34 were registered for prospective studies, and only three were tested on patients.
The evidence here is a systematic analysis of the FDA registry (PLOS Digital Health, Journal of Medical Internet Research), not hospital practice. The focus is on the gap between the approval system and evidence requirements.
7 stories · 0 of them Hungarian → lasting · evidence: moderate Hospital testing and governance lagging behind A report states that 93% of hospitals use AI, but only 44% have tested it properly. According to CCM (UPMC) and KLAS, 63% of healthcare systems lack an advanced AI strategic framework. Hospitals must prioritize the flood of Epic AI features themselves.
The actor is the introducing institution. The mechanism involves lagging internal testing and oversight, the burden of prioritization, and workflow integration. Nurses are excluded from decisions, while the Seattle Children's AI Review Board is one institutional response to prioritization. The evidence comprises reports, analysis, and executive and nurse accounts, not regulatory data.
7 stories · 0 of them Hungarian ↗ rising · evidence: moderate Shadow AI and unapproved tools According to Imprivata data, nearly three-quarters of healthcare systems deploy AI tools without formal IT approval. Unauthorized AI use by staff has already led to patient data incidents: Johns Hopkins Bayview Medical Center notified approximately 3,182 patients. Incidents also occurred at Weill Cornell Radiology and two psychiatric institutions within the Washington DSHS.
This is not about approved institutional deployment but about deployment without formal approval and clinicians' use of AI without permission. The evidence is a specific data protection incident and its notification.
4 stories · 0 of them Hungarian → lasting · evidence: moderate Missing real-world and prospective validation Clinical AI evidence is not keeping pace with deployment. For mammography AI, there is little data on prospective utility and workflow impact, clinical benefit is uncertain, and models are not necessarily interchangeable. Researchers and professional societies are calling for studies in real clinical settings, more real-world data, and better benchmarks.
The actors are researchers and professional associations; the subject is the methodology of proof: benchmarks, follow-up time, real-world testing, and model interchangeability. It is not about the number of approvals or hospital governance.
8 stories · 0 of them Hungarian Sub-thread stories Number of approvals versus clinical evidence Key actors: PLOS Digital Health, Journal of Medical Internet Research, FDA
Aug 17, 2026 FDA has authorized more than 1,500 AI devices, but evidence is lagging doctor Authorized status alone does not indicate clinical benefit, so the validation behind a purchased device should be asked about separately.hospital manager In procurement, local or prospective evidence should be requested from the vendor; the FDA list alone is not enough.medtech company Given the evidence gap, companies should expect stronger demands for clinical substantiation.Aug 25, 2026 Analysis: FDA's AI device list holds 1,430 authorized devices for 1995–2025 medtech company The specialty distribution shows which clinical areas are crowded or still empty in the AI device market.health policy The registry analysis provides data for regulatory monitoring of how AI devices spread across specialties.Aug 31, 2026 Of 1,357 FDA-cleared AI devices, only three were tested on patients doctor Clearance of operating-room AI tools does not mean effectiveness has been shown in patients, so clinicians should ask separately for clinical evidence.medtech company The lack of clinical validation risks tighter expectations from regulators and buyers.hospital manager At procurement, hospitals should ask manufacturers for prospective patient studies.Sep 8, 2026 Fewer than 1% of FDA-cleared AI devices tested for clinical benefit hospital manager In procurement, ask the vendor for patient outcome evidence rather than accepting FDA clearance alone.doctor Clearance does not mean proven clinical benefit, so a device's results should be treated critically.medtech company A lack of patient outcome data can be a competitive disadvantage in evidence-based purchasing.Sep 14, 2026 Evidence for medical AI effectiveness is lacking: only 34 of 1,357 FDA-authorized devices registered for prospective studies doctor Regulatory authorization alone is not evidence of clinical effectiveness, so when choosing a device it is worth asking for prospective data.hospital manager Procurement should require real-world clinical validation.medtech company The lack of prospective evidence is a market and credibility risk.health policy Pressure for regulatory requirements on proof of effectiveness may grow.Oct 12, 2026 FDA has cleared more than 1,600 AI medical devices; warning letter flags software updates medtech company The FDA scrutinises change-management documentation for algorithm updates and cloud migrations.doctor Because radiology AI dominates, experience of using it is greatest in that field.Oct 26, 2026 FDA-cleared AI devices pass 1,000, but their value in hospitals is uneven hospital manager In procurement, clearance alone is not enough; evidence from real-world use is also needed.medtech company In a crowded market, hospital integration and evidence will be the differentiators.Hospital testing and governance lagging behind Key actors: CCM (UPMC) and KLAS, AMA and CHAI, Seattle Children's AI Review Board, nurses
Aug 3, 2026 AI adoption outpaces governance: 63% of health systems lack an advanced AI strategy framework hospital manager Set up an AI governance committee and a post-launch maintenance process, not just a process for deployment.health IT Oversight must also cover AI features embedded in ERP and other systems.Aug 11, 2026 Nurses demand a say in clinical AI rollout, saying tools arrive without bedside review hospital manager Bedside user review must be built into the process before AI is deployed.Aug 17, 2026 93% of hospitals use AI, but only 44% have tested it properly hospital manager A formal process is needed to test and oversee AI tools.health IT A validation and monitoring framework must be built for the tools in use.doctor The AMA urges guardrails for the use of AI in healthcare.Aug 28, 2026 Hospitals adopt AI, but testing and oversight lag behind hospital manager A regime for testing, monitoring and accountability before and after deploying AI tools has to be established.doctor It is worth learning how the AI tools in use were validated and where they fail before they are built into the workflow.health IT The lack of AI governance processes is a risk for deployments.Sep 7, 2026 ChatGPT for Healthcare to be integrated into Epic as nurses question its safety health IT A safety and data-protection impact assessment of the Epic integration should be completed before rollout.hospital manager Involve nursing leadership in the deployment decision to avoid resistance later.Sep 21, 2026 Hospital AI governance: Epic's flood of features, 'scale, pause or stop' and advice from leaders hospital manager Managing AI tools requires a formal AI review board and a portfolio approach: scale, pause or stop.health IT The flood of AI features from EHR vendors must be filtered through a system of prioritisation and validation.Nov 5, 2026 Where the human-AI workflow in health care breaks down: hospitals should examine their tech stacks first hospital manager Before procurement, integrations and data quality need to be reviewed, because the value of an AI tool depends on them.health IT Record integration and terminology standardization are prerequisites for diagnostic AI.Shadow AI and unapproved tools Key actors: Imprivata, Johns Hopkins Bayview Medical Center, Weill Cornell, Washington State DSHS
Missing real-world and prospective validation Key actors: ASCO, the authors of AMIE, Carnegie Mellon, MLCommons
Aug 10, 2026 AI clinical decision support is spreading faster than the evidence behind it doctor Treat AI suggestions critically, because physicians too can come to lean on machine classifications.hospital manager Deployment requires validation and monitoring on the hospital's own patient population.health policy Evidence standards will have to be developed to keep pace with the speed of adoption.Aug 11, 2026 AI tools may fall short of breast radiologists' expectations in practice doctor In breast screening, AI should be validated in the local workflow before its benefit is counted on.hospital manager When procuring mammography AI, hospitals should ask for prospective evidence.Sep 2, 2026 ASCO: clinical AI needs more and better benchmarks doctor The lack of independent benchmarks calls for caution when evaluating oncology AI tools.Sep 7, 2026 AI in breast screening can clear some mammograms without radiologist review, but clinical benefit is uncertain doctor The radiologist's role in the screening protocol is changing, so sample-based checks of AI reads are worth setting up.hospital manager When planning AI for screening programmes, demand real, local outcome data.medtech company A standalone clearing function will require stricter evidence from regulators and buyers.Sep 18, 2026 Multicentre mammography study: adjunctive AI raises breast cancer detection by more than 10 percent doctor The result supports AI assistance in screening programmes, but the short follow-up calls for caution in interpreting it.Sep 23, 2026 Medical AI benchmarks: Carnegie Mellon's 'Synthetic Hospital', MLCommons and AMIE authors' critique doctor A model's benchmark results do not demonstrate clinical reliability with long patient records.health IT AI procurement should require local testing on real data.Sep 29, 2026 Medical AI devices should be tested in real-world settings, but most in hospitals are not hospital manager When procuring, it should ask the manufacturer for validation data from real-world conditions.medtech company It should collect performance data in clinical settings, including after authorisation.health policy Post-market evaluation based on real-world use is a regulatory question.Oct 13, 2026 Mammography AI: models are not interchangeable, hybrid reading could cut workload by about 40% doctor For radiologists, interchangeability of models is not automatic, and procurement requires local validation.hospital manager Reducing screening workload can be significant for capacity planning.Google search interest Google Trends relative search index over the period studied, weekly average. A narrative and its sub-threads appear in a single comparison: 100 is the group's most-searched day, and the figures can only be compared within the group. The search term was chosen by machine analysis; it measures how much the term is searched, not how widespread the narrative is.
Who is affected and how hospital manager FDA approval is not local validation. Create an AI Review Board (like Seattle Children's) that decides on scaling, suspension, and shutdown. Assess the existing technological background before purchasing new tools. doctor Ask on which population and with which test the tool was validated before relying on its output. Ensure you do not draw causal conclusions from AI classification. medtech company Without outcome data measured prospectively in real-world clinical settings, regulatory approval will increasingly not be enough to earn hospital trust. Document algorithm updates and cloud migration, because the FDA has already issued a warning letter over this. health policy Demand testing in real clinical environments and comparable benchmarks similar to those for oncology AI. Tie funding to post-hoc outcome data reporting. Hungary During the period under review, domestic presence is negligible or absent: no [HU] source among the stories supporting the narrative.
Weekly trend Supporting stories per week
2 Aug 3–9: 1 Aug 10–16: 2 Aug 17–23: 2 Aug 24–30: 2 aug. 31 – Sep 6: 2 Sep 7–13: 1 Sep 14–20: 2 Sep 21–27: 1 szept. 28 – Oct 4: 1 Oct 5–11: 0 Oct 12–18: 1 Oct 19–25: 0 okt. 26 – Nov 1: 1 Nov 2–8: 1 Aug 3–9 Nov 2–8
Turning points Aug 17, 2026 93% of hospitals use AI, but only 44% have tested it properly The pair of figures "93% use it, 44% tested it properly" condensed the lag into a single quotable number. Aug 31, 2026 Of 1,357 FDA-cleared AI devices, only three were tested on patients According to a PLOS Digital Health review, only three of the 1,357 FDA-approved devices were tested on patients. This has shifted attention to the validation gap behind approvals. Sep 14, 2026 Most health systems deploy AI tools without formal IT approval According to Imprivata data, nearly three-quarters of systems deploy AI tools without formal IT approval. This reveals that the gap exists not only with regulators but also within hospitals. Related narratives in the News magazine Supporting stories Aug 3, 2026 AI adoption outpaces governance: 63% of health systems lack an advanced AI strategy framework hospital manager Set up an AI governance committee and a post-launch maintenance process, not just a process for deployment.health IT Oversight must also cover AI features embedded in ERP and other systems.Aug 10, 2026 AI clinical decision support is spreading faster than the evidence behind it doctor Treat AI suggestions critically, because physicians too can come to lean on machine classifications.hospital manager Deployment requires validation and monitoring on the hospital's own patient population.health policy Evidence standards will have to be developed to keep pace with the speed of adoption.Aug 11, 2026 AI tools may fall short of breast radiologists' expectations in practice doctor In breast screening, AI should be validated in the local workflow before its benefit is counted on.hospital manager When procuring mammography AI, hospitals should ask for prospective evidence.Aug 17, 2026 FDA has authorized more than 1,500 AI devices, but evidence is lagging doctor Authorized status alone does not indicate clinical benefit, so the validation behind a purchased device should be asked about separately.hospital manager In procurement, local or prospective evidence should be requested from the vendor; the FDA list alone is not enough.medtech company Given the evidence gap, companies should expect stronger demands for clinical substantiation.Aug 17, 2026 93% of hospitals use AI, but only 44% have tested it properly hospital manager A formal process is needed to test and oversee AI tools.health IT A validation and monitoring framework must be built for the tools in use.doctor The AMA urges guardrails for the use of AI in healthcare.Aug 25, 2026 Analysis: FDA's AI device list holds 1,430 authorized devices for 1995–2025 medtech company The specialty distribution shows which clinical areas are crowded or still empty in the AI device market.health policy The registry analysis provides data for regulatory monitoring of how AI devices spread across specialties.Aug 28, 2026 Hospitals adopt AI, but testing and oversight lag behind hospital manager A regime for testing, monitoring and accountability before and after deploying AI tools has to be established.doctor It is worth learning how the AI tools in use were validated and where they fail before they are built into the workflow.health IT The lack of AI governance processes is a risk for deployments.Aug 31, 2026 Of 1,357 FDA-cleared AI devices, only three were tested on patients doctor Clearance of operating-room AI tools does not mean effectiveness has been shown in patients, so clinicians should ask separately for clinical evidence.medtech company The lack of clinical validation risks tighter expectations from regulators and buyers.hospital manager At procurement, hospitals should ask manufacturers for prospective patient studies.Sep 2, 2026 ASCO: clinical AI needs more and better benchmarks doctor The lack of independent benchmarks calls for caution when evaluating oncology AI tools.Sep 8, 2026 Fewer than 1% of FDA-cleared AI devices tested for clinical benefit hospital manager In procurement, ask the vendor for patient outcome evidence rather than accepting FDA clearance alone.doctor Clearance does not mean proven clinical benefit, so a device's results should be treated critically.medtech company A lack of patient outcome data can be a competitive disadvantage in evidence-based purchasing.Sep 14, 2026 Evidence for medical AI effectiveness is lacking: only 34 of 1,357 FDA-authorized devices registered for prospective studies doctor Regulatory authorization alone is not evidence of clinical effectiveness, so when choosing a device it is worth asking for prospective data.hospital manager Procurement should require real-world clinical validation.medtech company The lack of prospective evidence is a market and credibility risk.health policy Pressure for regulatory requirements on proof of effectiveness may grow.Sep 14, 2026 Most health systems deploy AI tools without formal IT approval health IT Auditing unauthorised AI tools and putting data-security governance in place is an urgent task.hospital manager A regulated framework for AI use should be developed together with the departments.Sep 21, 2026 Hospital AI governance: Epic's flood of features, 'scale, pause or stop' and advice from leaders hospital manager Managing AI tools requires a formal AI review board and a portfolio approach: scale, pause or stop.health IT The flood of AI features from EHR vendors must be filtered through a system of prioritisation and validation.Sep 29, 2026 Medical AI devices should be tested in real-world settings, but most in hospitals are not hospital manager When procuring, it should ask the manufacturer for validation data from real-world conditions.medtech company It should collect performance data in clinical settings, including after authorisation.health policy Post-market evaluation based on real-world use is a regulatory question.Oct 12, 2026 FDA has cleared more than 1,600 AI medical devices; warning letter flags software updates medtech company The FDA scrutinises change-management documentation for algorithm updates and cloud migrations.doctor Because radiology AI dominates, experience of using it is greatest in that field.Oct 26, 2026 FDA-cleared AI devices pass 1,000, but their value in hospitals is uneven hospital manager In procurement, clearance alone is not enough; evidence from real-world use is also needed.medtech company In a crowded market, hospital integration and evidence will be the differentiators.Nov 5, 2026 Where the human-AI workflow in health care breaks down: hospitals should examine their tech stacks first hospital manager Before procurement, integrations and data quality need to be reviewed, because the value of an AI tool depends on them.health IT Record integration and terminology standardization are prerequisites for diagnostic AI.Machine analysis based on story titles and summaries, with a verification pass. The source of the facts is the article linked at each story.